Dana Ullman's Testimony to the FDA on Homeopathic Medicine

23rd September 2015

The U.S. Food and Drug Administration (FDA) is presently re-evaluating regulation of homeopathic medicines (1). Below is excerpt of the testimony provided to the FDA by Dana Ullman, MPH, CCH:


Before addressing the specific questions that the Food and Drug Administration (FDA) poses in the Federal Register notice announcing a public hearing on the regulation of homeopathic medicines, it is first important to address the areas of special interest that seem to have led to the hearings (references will not be provided in this summary, only in the primary part of this testimony):

  1. The FDA asserts that the homeopathic industry has grown substantially, and it quotes a National Health Interview Survey, conducted by the Centers for Disease Control and Prevention's National Center for Health Statistics in 2007, that estimated that adults spent about 2.9 billion on the purchase of homeopathic medicine. The information provided below will show that the sales and popularity of homeopathic medicine has grown each decade since the 1970s, the government's figures are inflated substantially, are not accurate figuresof the sales of homeopathic medicines in the United States, and seems to include sales of many non-homeopathic products.